mRNA based vaccines and therapeutics – Nobel prize findings in action

SFT Seminarium December 12, 2023:

mRNA based vaccines and therapeutics
– Nobel prize findings in action


Patrik Andersson & Martin Billger, AstraZeneca R&D

01.

Patrik Andersson

Senior Director RNA Therapeutics Safety, Clinical Pharmacology and Safety Sciences, AstraZeneca R&D, Gothenburg

Patrik received his PhD in Toxicology at Karolinska Institutet, Stockholm in 2003 followed by a short postdoc periodat Gothenburg University. He joined AstraZeneca in Gothenburg, Sweden 2004 as Discovery Toxicologist, supporting small molecule projects in the discovery phase with a specific focus on on-target safety assessment. Since 2012, his focus has been safety and delivery of therapeutic antisense oligonucleotides and mRNA. During these years he has worked in a number of ASO and mRNA projects run jointly with Ionis, Regulus, moderna and Ethris.

Martin Billger

Senior Director, CVRM Safety, Clinical Pharmacology and Safety Sciences, AstraZeneca R&D, Gothenburg

02.

Martin received his PhD in zoophysiology at Göteborg University in 1993 followed by a postdoc at VanderbiltUniversity. He joined AstraZeneca in Gothenburg, Sweden 1997, initially as protein formulation scientist supporting both injectable recombinant proteins and oral vaccine projects.Since 2003 and to this day, he held different roles in drug toxicology supporting various drug modalities from early stage through clinical development and registered medicines.